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Abstract
Background: In the endometrium the steroid hormone progesterone (P), acting through its
nuclear receptors, regulates the expression of specific target genes and gene networks required
for endometrial maturation. Proper endometrial maturation is considered a requirement for
embryo implantation. Endometrial receptivity is a complex process that is spatially and temporally
restricted and the identity of genes that regulate receptivity has been pursued by a number of
investigators.
Methods: In this study we have used high density oligonucleotide microarrays to screen for
changes in mRNA transcript levels between normal proliferative and adequate secretory phases in
Rhesus monkey artificial menstrual cycles. Biotinylated cRNA was prepared from day 13 and days
21–23 of the reproductive cycle and transcript levels were compared by hybridization to
Affymetrix HG-U95A arrays.
Results: Of ~12,000 genes profiled, we identified 108 genes that were significantly regulated during
the shift from a proliferative to an adequate secretory endometrium. Of these genes, 39 were up-
regulated at days 21–23 versus day 13, and 69 were down-regulated. Genes up-regulated in P-
dominant tissue included: secretoglobin (uteroglobin), histone 2A, polo-like kinase (PLK),
spermidine/spermine acetyltransferase 2 (SAT2), secretory leukocyte protease inhibitor (SLPI) and
metallothionein 1G (MT1G), all of which have been previously documented as elevated in the
Rhesus monkey or human endometrium during the secretory phase. Genes down-regulated
included: transforming growth factor beta-induced (TGFBI or BIGH3), matrix metalloproteinase 11
(stromelysin 3), proenkephalin (PENK), cysteine/glycine-rich protein 2 (CSRP2), collagen type VII
alpha 1 (COL7A1), secreted frizzled-related protein 4 (SFRP4), progesterone receptor membrane
component 1 (PGRMC1), chemokine (C-X-C) ligand 12 (CXCL12) and biglycan (BGN). In addition,
many novel/unknown genes were also identified. Validation of array data was performed by semi-
quantitative RT-PCR of two selected up-regulated genes using temporal (cycle day specific)
endometrial cDNA populations. This approach confirmed up-regulation of WAP four-disulfide
core domain 2 (WFDC2) and SLPI during the expected window of receptivity.
Conclusion:  The identification of P-regulated genes and gene pathways in the primate
endometrium is expected to be an important first step in elucidating the cellular processes
necessary for the development of a receptive environment for implantation.
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Background
The endometrium is a complex, specialized organ that
plays critical roles in menstruation, embryo implantation
and pregnancy in women. Normal human endometrium
exhibits a 28 day cycle which is strictly controlled by the
changing pattern of the ovarian sex steroids estrogen (E)
and progesterone (P). Endometrial growth, differentia-
tion, shedding and reconstruction are expected to be reg-
ulated by hormone-induced changes in gene expression
during the menstrual cycle. It is the sequential secretion of
E and P that leads to orderly regulation of signal transduc-
tion pathways invoking a wide variety of genes including
ligands, receptors, cytokines, growth factors, extra-cellular
matrix proteins and enzymes involved in cellular metabo-
lism [1-5]. The action of these genes causes a shift from a
proliferative to a secretory (differentiated) state that is
accompanied by massive metabolic changes and struc-
tural remodelling necessary for correct maturation of a
'receptive' endometrium that can allow embryo implanta-
tion [1,2,6,7]. In humans the luminal endometrial epithe-
lium becomes receptive due to the presence of P after E
priming and the implantation window begins 4–5 days
and ends 9–10 days after exposure to P, limiting this
period to days 19–24 of the menstrual cycle [8]. The pre-
cise molecular mechanisms that act to achieve temporal
and spatial control of gene expression in the primate
endometrium to attain a state of receptivity (window of
implantation) are largely unknown. P action has, how-
ever, been shown to be essential for proper endometrial
maturation and the maintenance of pregnancy and these
effects of P are expected to be mediated primarily through
its cognate receptor (PR) [9,10].
One of the major objectives of our laboratory is the iden-
tification of P-regulated genes in Rhesus monkey
endometrium and their potential function in endometrial
maturation. Previous studies in humans [11-14] and
other animal models [15-17] have identified several fac-
tors that may be implicated in endometrial maturation
and receptivity. It is apparent that no single factor is
responsible for preparation of the endometrium for recep-
tivity, but more likely that controlled expression of many
genes in a temporal fashion eventually leads to a proper
uterine environment for implantation.
Recent technological advances in DNA microarrays has
allowed the simultaneous monitoring of expression of
thousands of genes in one experiment, facilitating a global
view of molecular events during physiological functions
and cellular processes. Prior to the publication of four
recent papers [11,18-20] studies on human and primate
endometrial gene expression during the menstrual cycle
were primarily limited to individual genes. Correct matu-
ration of the endometrium necessary for receptivity of the
developing blastocyst and subsequent pregnancy is a pre-
cisely coordinated multi-step process involving many fac-
tors that requires regulated expression of large sets of
genes. To date there is limited evidence for genetic mark-
ers that describe/predict a receptive endometrium capable
of embryo implantation in the human and non-human
primate.
We have previously described the construction of tempo-
ral (cycle day specific) endometrial cDNA populations
from Rhesus monkey artificial menstrual cycles [21]. The
current study used Affymetrix HG-U95A microarrays to
simultaneously compare the expression of ~12000 genes
between the E-dominant proliferative phase (day 13) and
the P-dominant secretory phase (window of receptivity,
days 21–23) in the Rhesus monkey. The use of human
gene chips for non-human primate cross-species hybridi-
zation has been validated due to the high conservation of
gene sequences between the species [22]. Our results
show that the transition from an E-dominant to a P-dom-
inant (receptive) endometrium involves both P-depend-
ent up-regulation and down-regulation of genes.
Methods
Animal Model – Rhesus Monkey
The development and use of artificial menstrual cycles in
the Rhesus monkey was first described by Hodgen [23].
These studies showed that simulation of the menstrual
cycle by the timed insertion and removal of silastic
implants of E or P was sufficient to allow the
endometrium to support implantation and eventual
delivery (IVF and surrogate transfer). Our previously pub-
lished studies [24-27] describe in detail the protocols for
creation of adequate cycles. All protocols used in these
studies were approved by the Institutional Animal Care
and Use Committee.
Tissue Collection and RNA Preparation
Tissue was collected by endometriectomy at hysterotomy
as previously described [26,28]. Tissue harvesting was per-
formed prior to insertion or removal of implants from 3
individual animals for each of days 13, 21, and 23 of the
menstrual cycle, and stored at -80°C until further process-
ing. Total RNA was isolated and poly(A)+-enriched RNA
was prepared using oligo d(T) spin columns. The integrity
of all total mRNA samples was examined by visual inspec-
tion of intact 28S and 18S ribosomal RNA bands on agar-
ose gels prior to further processing. Samples were treated
with DNase I to ensure the removal of traces of genomic
DNA.
Synthesis and amplification of cDNA populations
One microgram of poly(A)+ RNA from three animals (n =
3) for each time point (days 13, 21, and 23) was pooled
just prior to cDNA synthesis (a total of 3 µg per time
point). The Superscript™ Choice System (LifeReproductive Biology and Endocrinology 2004, 2:54 http://www.rbej.com/content/2/1/54
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Technologies, Rockville, MD), was used for cDNA synthe-
sis using the same procedure as previously described [21].
Microarray hybridization
For probe preparation, 2 micrograms of day 13 cDNA and
one microgram each of days 21 and 23 cDNA (pooled)
were converted into biotinylated cRNA by in vitro tran-
scription (IVT) using the ENZO BioArray High Yield RNA
T7 Transcription Labelling Kit (ENZO, Farmingdale, NY).
After a 37°C incubation step for 6 h, the labelled cRNA
was cleaned up by phenol/chloroform extraction and eth-
anol precipitation, and quantitated spectrophotometri-
cally by absorbance at 260 nm. Typically, each IVT
reaction yielded ~50 ug. A total of five probe sets for both
day 13 and days 21–23 were prepared (N = 5) for hybrid-
ization to Affymetrix Human Genome U95A oligonucle-
otide microarrays (Affymetrix, Santa Clara, CA),
corresponding to 12,686 human genes and expressed
sequence tags (EST's). 15 micrograms of cRNA was chem-
ically fragmented in 5X fragmentation buffer (200 mM
Tris, pH 8.1; 500 mM KOAc; 150 mM MgOAc) and was
added to a hybridization cocktail containing 50, 1.5, 5.0,
25 and 100 pM respectively of prokaryotic gene oligonu-
cleotide hybridization controls B2, bioB, bioC, bioD and cre
(biotin synthesis pathway genes of E.coli,  [Affymetrix,
Santa Clara, CA]), 0.1 mg/ml herring sperm DNA, 0.5 mg/
ml acetylated BSA, 100 mM MES, 1 M [Na+], 20 mM EDTA
and 0.01% Tween. Arrays were hybridized for 16 h on an
Affymetrix GeneChip fluidics station at the University of
Massachusetts Medical School Genomics Core Facility.
Washing, fluorescent staining and scanning for data gen-
eration for subsequent analysis were conducted in the
Genomics Core Facility at UMass Medical School.
Statistical analysis
Analysis of gene expression data from Affymetrics Gene-
Chip® experiments was performed at the Bioinformatics
facility at UMass Medical School, in a two step process:
1. In the first step, model based expression estimates were
made using the method of Li and Wong [29]. These esti-
mates were expressed as logs with base 2.
2. In the second step, differentially expressed genes were
identified by performing Analysis of Variance (ANOVA)
for mixed models [30] on all genes with the series of
microarrays as a random factor and with treatment as a
fixed factor.
The genes were then sorted in ascending order by the p-
value of the treatment effect from the ANOVA. The subset
of differentially expressed genes were those genes with a p-
value less than or equal to the p-value for a gene with a
False Discovery Rate (FDR) [31] of 5% (analogous to a sig-
nificance level of 0.05). Estimates of the effects expressed
as fold changes were made by taking the antilog base 2 of
the treatment effect estimates from the Mixed Model
ANOVA. Model based expression estimates based on the
Li and Wong method were made using the dChip software
package [29]. Analysis of Variance for Mixed Models were
made using PROC MIXED in the SAS Statistical Analysis
Software Package [32-34]. Post ANOVA analyses includ-
ing analysis for FDR and fold change were made using
Microsoft Excel. Genes that are differentially expressed >2-
fold with an FDR <5% are listed in Tables 1 and 2.
Semi-quantitative RT-PCR
Specific amplimers were designed for SLPI and WFDC2
(see below) and used in PCR reactions with six endome-
trial cycle day-specific cDNA populations (day 13,14, 17,
21, 23, and 26)[21] as template to confirm their expres-
sion patterns. 40 ng of template were analyzed in 100 µl
reactions containing 0.5 µM fragment-specific primers,
0.25 mM dNTPs, 1.5 mM MgCl2, 1x buffer and 2 units taq
polymerase in a thermal cycler (94°C, 1 minute; 48–
55°C, 1 minute; 72°C, 2 minutes). PCR reactions were
done for 24–45 cycles to determine the linear range of
amplification for each primer set. Products were analyzed
by agarose gel electrophoresis and comparative evaluation
was performed by densitometric analysis (QuantiScan,
Biosoft Inc.) of photographed gels. Amplimer sequences
were as follows:
SLPI: 5'-AGCTTAACGAGGGAGGAAGC-3' & 5'-AAAG-
GACCTGGACCACACAG-3' (30 cycles); WFDC2: 5'-
CGGCTTCACCCTAGTCTCAG & 5'-ATTTCATCT-
GGCCAGGACAC (25 cycles).
Results
Microarray hybdridization data analysis
A common problem when assaying the expression of
thousands of transcripts in complex organs is biological
and experimental variability. Variation in gene expression
can arise not only from cellular heterogeneity of individ-
ual samples and genetic differences among the popula-
tion, but also by mechanisms independent of genetics
under identical conditions (experimental variation). In
order to reduce such variability encountered in microarray
analysis, cRNA from three Rhesus monkeys in the prolif-
erative phase (day 13; n = 3) and six monkeys in secretory
phase (day 21; n = 3 and 23; n = 3) were separately pooled
and used as probes on human U95 oligonucleotide arrays
and a total of five hybridizations were performed for both
probe sets (n = 5).
The data were analyzed as detailed in Methods and a min-
imal change of 2-fold was adopted to select up- and
down-regulated genes. As can be seen in the scatter plot of
normalized data (Figure 1), the vast majority of genes dis-
played <2-fold change of expression between proliferativeReproductive Biology and Endocrinology 2004, 2:54 http://www.rbej.com/content/2/1/54
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and secretory phases. Many of these genes have previously
been shown to exhibit little or no differential expression
during the menstrual cycle. Using a FDR/P value of <5.0%
to identify statistical significance between the two groups
of data, 39 genes exhibited up-regulation and 69 genes
exhibited down-regulation during the shift from a prolif-
erative to secretory endometrium.
Tables 1 and 2 list the genes that we found up- or down-
regulated respectively in the secretory phase. Their
potential endometrial function and associated biological
pathway were assessed by searches of LocusLink (NCBI),
NETAFFX (Affymetrix), KEGG and BioCarta databases
and gene ontology/annotation tools. Of the significantly
regulated genes, we identified six genes previously shown
by our laboratory and other investigators (see table 1 for
references) to be up-regulated directly or indirectly by pro-
gesterone in human secretory phase endometrium: secre-
toglobin (uteroglobin), histone 2A, polo-like kinase
(PLK), spermidine/spermine acetyltransferase 2 (SAT2),
secretory leukocyte protease inhibitor (SLPI) and metal-
lothionein 1G (MT1G). We also identified nine genes pre-
viously shown (see table 2 for references) to be down-
regulated in secretory versus proliferative phase human
endometrium: transforming growth factor beta-induced
(TGFBI or BIGH3), matrix metalloproteinase 11 (strome-
lysin 3), proenkephalin (PENK), cysteine/glycine-rich
protein 2 (CSRP2), collagen type VII alpha 1 (COL7A1),
secreted frizzled-related protein 4 (SFRP4), progesterone
receptor membrane component 1 (PGRMC1), chemokine
(C-X-C) ligand 12 (CXCL12) and biglycan (BGN).
Confirmation of microarray data by RT-PCR
We have previously shown by differential display and RT-
PCR that one of the genes up-regulated during the secre-
tory phase in the microarray analysis, SLPI, was expressed
in a temporally restricted manner during the expected
window of implantation (days 17–23) [21]. We have
expanded these data to include temporal endometrial
cDNA populations from days 13–26 and further confirm
the elevated expression of SLPI during days 21–23 com-
pared to day 13 (Figure 2). Another gene that was highly
up-regulated (27.5-fold) in the microarrays, WAP four-
disulfide core domain 2 (WFDC2), is also a member of
the same family as SLPI (Whey Acidic Proteins). We
selected this gene in addition for semi-quantitative RT-
PCR analysis using our temporal endometrial cDNA pop-
ulations as template for validation of the microarray pro-
cedure. Figure 2 shows that indeed, WFDC2 expression is
predominantly up-regulated between day 13 and days
17–23 of the secretory phase. These results are consistent
with the microarray data and demonstrate the temporal
expression of the above two genes, i.e. coincident and
restricted to the window of implantation.
Discussion
Advances in gene expression profiling aided by high
throughput microarray screening of thousands of genes
has allowed a relatively unbiased approach toward identi-
fying genes, gene families and signalling pathways that are
candidates for endometrial receptivity. The availability of
this technology makes it possible to investigate global
changes in gene expression that accompany the transition
from a proliferative to secretory endometrium and facili-
tates the identification of molecular mechanisms underly-
ing implantation and the expression signature of genes
during the window of receptivity. These studies provide
an avenue for design of diagnostic tests for endometrial
disorders and for targeted drug discovery for the treatment
of implantation-based infertility and endometrial-based
contraception. In these studies we have used microarray
gene expression profiling to identify genes/gene networks
that are differentially expressed in the proliferative versus
secretory endometrium of the Rhesus monkey.
Genes up-regulated during secretory phase
Secretory leukocyte protease inhibitor (SLPI): Our labora-
tory has previously shown by differential display and RT-
PCR that SLPI was expressed in a temporally restricted
Normalization plot of microarray data Figure 1
Normalization plot of microarray data Normalization 
plot from a representative analysis of changes in gene expres-
sion between day 13 (proliferative, y axis) and days 21–23 
(secretory, x axis) endometrium. The blue line is the diagonal 
y = x, the red circles are the probes selected in the "invariant 
set" and the green curve indicates the running median nor-
malization curve based on the "invariant set".
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manner in Rhesus endometrium during the expected win-
dow of implantation [21], in agreement with its up-regu-
lation during the secretory phase described in this
microarray study. SLPI is a neutrophil elastase inhibitor
which also has antibacterial and anti-inflammatory prop-
erties. King et al [35] showed that endometrial expression
was menstrual cycle dependent with increased secretion
in the secretory phase and the main site of SLPI synthesis
in endometrium and decidua was found to be the glandu-
lar epithelium. Furthermore, progesterone treatment
increases expression of SLPI mRNA and protein and this
up-regulation is attenuated in the presence of the anti-
progestogen, RU486 [36]. An antibiotic role for SLPI in
the endometrium and decidua during implantation and
pregnancy would be consistent with the expression profile
and localization of SLPI. This is in agreement with a pre-
vious microarray profiling study in humans where SLPI
expression increased in secretory endometrium and par-
ticularly in receptive (day LH+7) compared to pre-recep-
tive (day LH+2) endometria [19]. SLPI has also been
shown to be involved in the control of tissue remodelling
(epithelialization) and wound healing pathways in SLPI-
null mice [37,38]. Because increased SLPI expression
coincides with the window of endometrial receptivity it
has been postulated that it may be have a role in implan-
tation, although the existence of viable SLPI-null mice
suggests it is not required for fertility in mice. SLPI belongs
to a family of 14 WAP proteins (Whey Acidic Proteins)
that have duplicated on chromosome 20 over evolution
[39]. Interestingly, one gene that was highly up-regulated
(27.5-fold) in the microarrays, WAP four-disulfide core
domain 2 (WFDC2), is also a member of the SLPI family
of secretory proteins and its expression profile was con-
firmed by RT-PCR in the current study. Although there is
little literature on WFDC2, it is interesting to speculate
that one or more of these uncharacterized family mem-
bers could provide functional redundancy regarding
endometrial development in the female reproductive
tract. Our data on SLPI and WFDC2 (figure 2) confirm the
microarray analysis and provide an important avenue for
future studies on their potentially important gene family
in endometrial function.
Secretoglobin/uteroglobin: Uteroglobin is a progesterone
binding protein, a member of the antiflammin gene fam-
ily and possibly a novel cytokine. Initially, uteroglobin
was identified as the major protein of rabbit uterine secre-
tion during the phase of preimplantation. Muller-Schottle
et al [40] show that secretory uteroglobin is found in
endometrial tissue homogenates in highest levels of
expression during the early luteal phase (days 15–19). In
turn, uteroglobin is released into the uterine lumen in
peak amounts during the receptive phase of the menstrual
cycle (mid-luteal phase, days 20–23). Immunohisto-
chemical studies match with these results, as uteroglobin
is located during the early and mid-luteal phase in the api-
cal compartments of endometrial gland cells. These obser-
vations strongly suggest an involvement of uteroglobin in
endometrial preparations for implantation. While uter-
oglobin appears as one of the most extensively studied
proteins, particularly its physico-chemical properties,
including its crystal structure and its gene, the true physi-
ological role of this protein still remains to be unravelled
[40].
Histone 2A: Beier-Hellwig et al [41] identified several
individual proteins that appear as characteristic markers
for the receptive stage of the luteal phase, including his-
tone H2A. In order to identify the endocrine dependency
of the proteins which significantly contribute to the
"receptive stage pattern," patients were treated with the
progesterone antagonist RU 486 at day LH +2. The assess-
ment 4 days later revealed diminished and missing bands
RT-PCR of selected genes Figure 2
RT-PCR of selected genes Expression of selected gene 
fragments SLPI (218 bp, panel A) and WFDC2 (266 bp, panel 
B) in temporal cDNA populations of Rhesus endometrium by 
semi-quantitative RT-PCR. cDNA Populations used in the 
microarray analysis were day 13 (proliferative phase, lane 1) 
and days 21–23 (secretory phase, lanes 4 and 5). Lane 7 is 
100 bp marker (M).
Day:    13    14   17    21  23   26            M
WFDC2
Lane:    1      2   3     4      5    6           7 B
A Lane:    1      2    3      4 5       6       7
Day:    13     14     17     21     23    26       M
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of the H2A-, H2B-, and H3-histones. These results
demonstrate progesterone-dependent components of the
endometrium at the receptive stage, which can be used as
useful markers for an improved precision in luteal phase
diagnostics.
Polo-like kinase: The enzyme, polo-like kinase (PLK), is a
mammalian serine/threonine kinase involved in cell cycle
regulation. Takai et al [42] showed that PLK staining was
detected in the basement membrane of many endometrial
glands, stromal cells, and some endothelial cells. The
number of PLK-positive endometrial gland cells was sig-
nificantly higher in the late proliferative phase and the
early secretory phase than in the early proliferative phase
or the late secretory phase. PLK expression seemed to be
correlated with the expression of Ki-67 and proliferating
cell nuclear antigen (PCNA) in many endometrial glands
and stromal cells particularly in the late proliferative
phase, reflecting a role of PLK in cellular proliferation.
Nevertheless, in the early secretory phase, at which point
the expression of Ki-67 and PCNA decreased in endome-
trial glands, PLK was strongly expressed. This finding sug-
gests that PLK may have some post-mitotic functions in
certain specialized cell types. Although the highest expres-
sion of PLK was observed in the late proliferative and the
early secretory phases, the expression drastically decreased
in the late secretory phase. These findings, taken together,
indicate that the expression of PLK in normal
endometrium fluctuates over the course of the menstrual
cycle, suggesting in turn that PLK is associated with hor-
mone-dependent cellular proliferation.
Spermidine/spermine  N1-acetyltransferase: Using the
mRNA differential display methodology, Green et al [43]
identified spermidine/spermine N1-acetyltransferase
(SSAT or SAT) as a porcine endometrial gene whose
expression is maximal at peri-implantation and which is
induced by conceptus-derived factors and by progester-
one. SSAT, by acetylating the naturally occurring
polyamines (PA) spermine and spermidine, typically
functions as a cell growth inhibitor. SSAT, through its con-
trol of intracellular PA levels, likely plays a modulatory
role in the establishment of an optimal uterine environ-
ment for successful embryo attachment [44]. SSAT was
also up-regulated in the secretory phase in an independ-
ent microarray study [20].
Genes down-regulated during the secretory phase
Betaig-H3 (BIGH3 or TGFBI): TGFBI is a transforming
growth factor β-induced extracellular matrix protein with
cell adhesion-promoting activity [45]. Carson et al [18]
found that TGFBI expression decreased by 92% by the
microarray analysis and >80% by Northern blot analysis
during the early to mid-luteal transition. This is in agree-
ment with our results that show a large decrease in expres-
sion during the secretory phase (24-fold). In a second
microarray study, Borthwick et al [20] also found that
BIGH3 was down regulated in secretory phase
endometrium.
Matrix metalloproteinase 11 (stromelysin 3 or MMP-11):
Matrix metalloproteinases are a highly regulated family of
enzymes that together can degrade most components of
the extracellular matrix. Using in situ hybridization, Rodg-
ers et al [46] show that transcripts for stromelysin-2 were
only detected in late secretory and menstrual
endometrium, while those for matrilysin and strome-
lysin-3 were consistently detected in proliferative
endometrium. In addition, endometrial expression of
matrix metalloproteinase (MMP)-3, MMP-7 and MMP-11
occurs during menstrual breakdown and subsequent
estrogen-mediated growth, but not during the secretory
phase, and these enzymes are suppressed by progesterone
treatment [47]. These data indicate that matrix metallo-
proteinases are expressed in cell-type, tissue, and repro-
ductive cycle-specific patterns, consistent with regulation
by steroid hormones, and with specific roles in the com-
plex tissue growth and remodeling processes occurring in
the endometrium during the reproductive cycle. In two
other microarray studies expression of stromelysin 3 was
also found to be decreased in the secretory phase [18,20].
Proenkephalin (PENK): Using Northern blots Low et al
[48] detected a strong band of proenkephalin mRNA of
1.3 kilobases almost exclusively in the proliferative
endometrium from monkeys in the follicular phase of the
cycle. No proenkephalin mRNA was detected in secretory
endometrium obtained from monkeys in the luteal phase.
Furthermore, proenkephalin mRNA was regulated by 17
beta-estradiol in the endometrium and this effect of estra-
diol was antagonized by progesterone. Borthwick et al
[20] and Carson et al [18] also found decreased expres-
sion of PENK during the secretory phase using microarray
analysis.
Secreted frizzled-related protein 4 (SFRP4 or FrpHE):
Microarray analysis has previously shown that FrpHE is
down-regulated during the window of implantation
[11,18,20]. FrpHE is an inhibitor of Wnt signaling [49]
and FrpHE inhibits Wnt action by competitive binding to
Wnt ligand(s). Wnt7A (-/-) null mice are infertile and
have complete absence of uterine glands and a reduction
in mesenchymally derived uterine stroma [50]. It is possi-
ble that the Wnt family may play a role in epithelial-
embryo and/or epithelial-stromal interactions and thus in
uterine receptivity. By in situ hybridization, Abu-Jawdeh
et al [51] have determined that frpHE is expressed by mes-
enchymal cells but not by epithelial cells. The expression
of frpHE is modulated during the endometrial cycle: it is
expressed in the stroma of proliferative endometrium andReproductive Biology and Endocrinology 2004, 2:54 http://www.rbej.com/content/2/1/54
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not significantly detectable in secretory or menstrual
endometrium, suggesting that frpHE is under hormonal
regulation. The data also indicates that frpHE functions as
a regulator of the Wnt-frizzled signaling pathway and is
involved in endometrial physiology. In an independent
study, FrpHE expression was detected in stromal cells,
with no evidence of expression by glandular cells. The pat-
tern of expression was dependent on the phase of the
menstrual cycle, with abundant expression in proliferative
endometrium, whereas secretory endometrium showed
little or no signal, consistent with RT-PCR and quantita-
tive PCR data [52].
Other genes that were down-regulated in the secretory
phase in this study and in independent microarray analy-
ses by other investigators were: cysteine/glycine-rich pro-
tein 2 (CSRP2) [11,19]; collagen type VII alpha 1
(COL7A1) [18]; progesterone receptor membrane com-
ponent 1 (PGRMC1 or Hpr6) [11,53]; chemokine C-X-C
ligand 12 (CXCL12) [18], and biglycan (BGN) [11].
Although gene microarrays have the potential to shed
light on cellular processes by identifying groups of genes
that appear to be differentially expressed, this "function
by association" approach has potential caveats in the view
of some investigators [54]. Some genes known to be
involved in a particular pathway can be missed whereas
other apparently unrelated genes exhibit expression pro-
files that are strikingly similar to known pathways. Also,
there is little consensus about how to interpret the gene
expression patterns of hypothetical genes, genes of
unknown function or transcripts identified only by
expressed sequence tags. Because statistical significance
does not always correlate with biological significance, we
have focused our attention on highly up- and down-regu-
lated genes whose expression profiles are consistent with
our previous studies and the literature and/or are known
components of cellular pathways. When identified genes
can be assigned to specific pathways, we can subsequently
study the expression profiles of functionally related genes
by PCR and other techniques in our cDNA populations.
Conclusions
The observation that more genes are down-regulated in
secretory endometrium than up-regulated has been noted
previously by Kao et al [11]. It is speculated that this is due
to a combination of both loss of E action (E up-regulated
genes in the proliferative phase) and direct or indirect
down regulation of genes by P in the secretory phase.
Although there is a degree of overlap in differentially
expressed genes between different microarray data sets in
the litereature, they are by no means similar. Some genes
expected to change in expression from a proliferative to
secretory endometrium were not found to change in our
analysis. A direct comparison between different studies is
difficult for several reasons. Not only are there disparities
in study designs, but also different software and statistics
were used to analyze the hybridization data. Also, because
the endometrium is a complex organ composed of many
compartments and cell types, gene products expressed in
multiple cell types may be differentially regulated at levels
that are undetectable in whole tissue analysis. In future
studies, we propose to address this potential shortcoming
by focusing on each cell type separately using laser capture
microdissection prior to mRNA isolation as previously
described by our laboratory [55].
This unbiased quantitative analysis of a large number of
genes during endometrial development has provided
results that agree with previous findings and has also iden-
tified several novel genes not previously known to be
expressed in the endometrium or to be steroid responsive.
Interpretation of these data with regard to their precise
functional roles in endometrial maturation must await
future studies.
Additional material
Acknowledgements
The authors thank Phyllis Spatrick for Affymetrics GeneChip® processing, 
and Stephen Baker and David Lapointe for statistical analysis of microarray 
data (Bioinformatics/Genomics Core Facility, UMMS, supported in part by 
the Diabetes Endocrinology Research Center, DK-32520, NIH). This work 
was supported in part by NICHD grant HD 31620 (WCO).
References
1. Bartelmez GW, Corner GW, Hartman CG: Cyclic changes in the
endometrium of the rhesus monkey (Macaca mulatta). Con-
trib Embryol 1951, 34:99-144.
2. Ferenczy A, Bergeron C: Histology of the human endometrium:
From birth to senescence. Ann NY Acad Sci 1991, 622:6-27.
3. Gurpide E, Tseng L: Induction of human endometrial oestradiol
dehydrogenase by progestins. Endocrinology 1975, 97:825-833.
4. Clarke CL, Sutherland RL: Progestin regulation of cellular
proliferation. Endocr Rev 1990, 11:266-301.
5. Fay TN, Grudzinskas JG: Human endometrial peptides:  A
review of their potential role in implantation and
placentation. Hum Reprod 1991, 6:1311-1326.
6. Bartelmez GW: The phases of the menstrual cycle and their
interpretation in terms of the pregnancy cycle. Am J Obstet
Gynecol 1957, 74:931-955.
Additional file 1
Table 1. Genes up-regulated during the secretory phase
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
7827-2-54-S1.doc]
Additional file 2
Table 2. Genes down-regulated during the secretory phase
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
7827-2-54-S2.doc]Reproductive Biology and Endocrinology 2004, 2:54 http://www.rbej.com/content/2/1/54
Page 8 of 9
(page number not for citation purposes)
7. Maslar IA: The progestational endometrium. Sem Reprod Endo
1988, 6:115-128.
8. Navot D, Bergh PA, Williams M, Garrisi GJ, Guzman I, Sandler B, Fox
J, Schreiner-Engel P, Hofmann GE, Grunfeld L: An insight into early
reproductive processes through the in vivo model of ovum
donation. J Clin Endocrinol Metab 1991, 72:408-414.
9. Savouret JF, Muchardt C, Quesne M, Mantel A, De The H, Milgrom E:
Regulation of the progesterone receptor functions. Annals of
the New York Academy of Sciences 1998, 839:138-142.
10. Conneely OM, Lydon JP: Progesterone receptors in reproduc-
tion: functional impact of the A and B isoforms. Steroids 2000,
65:571-577.
11. Kao LC, Tulac S, Lobo S, Imani B, Yang JP, Germeyer A, Osteen K,
Taylor RN, Lessey BA, Giudice LC: Global gene profiling in
human endometrium during the window of implantation.
Endocrinology 2002, 143:2119-2138.
12. Salamonsen LA, Nie G, Findlay JK: Newly identified endometrial
genes of importance for implantation. J Reprod Immunol 2002,
53:215-225.
13. Lessey BA: Adhesion molecules and implantation.  J Reprod
Immunol 2002, 55:101-112.
14. Martin J, Dominguez F, Avila S, Castrillo JL, Remohi J, Pellicer A,
Simon C: Human endometrial receptivity: gene regulation. J
Reprod Immunol 2002, 55:131-139.
15. Paria BC, Reese J, Das SK, Dey SK: Deciphering the cross-talk of
implantation: advances and challenges.  Science 2002,
296:2185-2188.
16. Puri CP, Katkam RR, Sachdeva G, Patil V, Manjramkar DD, Kholkute
SD:  Endometrial contraception: modulation of molecular
determinants of uterine receptivity. Steroids 2000, 65:783-794.
17. Carson DD, Bagchi I, Dey SK, Enders AC, Fazleabas AT, Lessey BA,
Yoshinaga K: Embryo implantation. Dev Biol 2000, 223:217-237.
18. Carson DD, Lagow E, Thathiah A, Al-Shami R, Farach-Carson MC,
Vermon M, Yuan L, Fritz M, Lessey B: Changes in gene expression
during the early to mid-luteal (receptive phase) transition in
human endometrium detected by high-density microarray
screening. Mol Hum Reprod 2002, 8:871-879.
19. Riesewijk A, Martin J, van Os R, Horcajadas JA, Polman J, Pellicer A,
Mosselman S, Simon C: Gene expression profiling of human
endometrial receptivity on days LH+2 versus LH+7 by
microarray technology. Mol Hum Reprod 2003, 9:253-264.
20. Borthwick JM, Charnock-Jones DS, Tom BD, Hull ML, Teirney R, Phil-
lips SC, Smith SK: Determination of the transcript profile of
human endometrium. Mol Hum Reprod 2003, 9:19-33.
21. Okulicz WC, Ace CI: Temporal regulation of gene expression
during the expected window of receptivity in the Rhesus
monkey endometrium.  Biology of Reproduction 2003,
69:1593-1599.
22. Chismar JD, Mondala T, Fox HS, Roberts E, Langford D, Masliah E,
Salomon DR, Head SR: Analysis of result variability from high-
density oligonucleotide arrays comparing same-species and
cross-species hybridizations. BioTechniques 2002, 33:516-8, 520,
522.
23. Hodgen GD: Surrogate embryo transfer combined with estro-
gen-progesterone therapy in monkeys.  Implantation, gesta-
tion, and delivery without ovaries. JAMA 1983, 250:2167-2171.
24. Longcope C, Bourget C, Meciak PA, Okulicz WC, McCracken JA,
Hoberg LM, Padykula HA: Estrogen dynamics in the female rhe-
sus monkey. Biol Reprod 1988, 39:561-565.
25. Okulicz WC, Savasta AM, Hoberg LM, Longcope C: Biochemical
and immunohistochemical analyses of estrogen and proges-
terone receptors in the rhesus monkey uterus during the
proliferative and secretory phases of artificial menstrual
cycles. Fertil Steril 1990, 53:913-920.
26. Okulicz WC, Balsamo M, Tast J: Progesterone regulation of
endometrial estrogen receptor and cell proliferation during
the late proliferative and secretory phase in artificial men-
strual cycles in the rhesus monkey. Biol Reprod 1993, 49:24-32.
27. Okulicz WC, Ace CI, Longcope C, Tast J: Analysis of differential
gene regulation in adequate versus inadequate secretory-
phase endometrial complementary deoxyribonucleic acid
populations from the rhesus monkey.  Endocrinology 1996,
137:4844-4850.
28. Ace CI, Balsamo M, Le LT, Okulicz WC: Isolation of progester-
one-dependent complementary deoxyribonucleic acid frag-
ments from rhesus monkey endometrium by sequential
subtractive hybridization and polymerase chain reaction
amplification. Endocrinology 1994, 134:1305-1309.
29. Li C, Wong WH: Model-based analysis of oligonucleotide
arrays: expression index computation and outlier detection.
Proceedings of the National Academy of Science 2001, 98:31-36.
30. McLean RA, Sanders WL, Stroup WW: A unified approach to
mixed linear models. American Statistician 1991, 45:54-64.
31. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a
practical and powerful approach to multiple testing. Journal of
the Royal Statistical Society 1995, 57:287-300.
32. Littell RC, Milliken GA, Stroup WW, Wolfinger RD: The SAS system
for mixed models. Carey,N.C., SAS Institute Inc; 1996. 
33. The MIXED Procedure. SAS Institute, Inc.; 1997:571-702. 
34. Littell R, Wolfinger R: Mixed model analysis of data with the
SAS system. . Walt Disney World Dolphin - Salon V. 8-12-1995.;
1995:1-93. 
35. King AE, Critchley HOD, Kelly RW: Presence of secretory leuko-
cyte protease inhibitor in human endometrium and first tri-
mester decidua suggests an antibacterial protective role.
Molecular Human Reproduction 2000, 6:191-196.
36. King AE, Morgan K, Sallenave JM, Kelly RW: Differential regulation
of secretory leukocyte protease inhibitor and elafin by
progesterone. Biochem Biophys Res Commun 2003, 310:594-599.
37. Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkarni AB, Greenwell-
Wild T, Hale-Donze H, McGrady G, Song XY, Wahl SM: Secretory
leukocyte protease inhibitor mediates non-redundant func-
tions necessary for normal wound healing. Nature Med 2000,
6:1147-1153.
38. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L, Erd-
jument-Bromage H, Tempst P, Wright CD, Ding A: Conversion of
proepithelin to epithelins: roles of SLPI and elastase in host
defense and wound repair. Cell 2002, 111:867-878.
39. Clauss A, Lilja H, Lundwall A: A locus on human chromosome 20
contains several genes expressing protease inhibitor
domains with homology to whey acidic protein.  Biochem J
2002, 368:233-242.
40. Muller-Schottle F, Classen-Linke I, Alfer J, Krusche C, Beier-Hellwig
K, Sterzik K, Beier HM: Expression of uteroglobin in the human
endometrium. Mol Hum Reprod 1999, 5:1155-1161.
41. Beier-Hellwig K, Sterzik K, Bonn B, Hilmes U, Bygdeman M, Gemzell-
Danielsson K, Beier HM: Hormone regulation and hormone
antagonist effects on protein patterns of human endometrial
secretion during receptivity. Ann N Y Acad Sci 1994, 734:143-156.
42. Takai N, Miyazaki T, Miyakawa I, Hamanaka R: Polo-like kinase
expression in normal human endometrium during the men-
strual cycle. Reprod Fertil Dev 2000, 12:59-67.
43. Green ML, Blaeser LL, Simmen FA, Simmen RCM: Molecular clon-
ing of spermidine/spermine N1-acetyltransferase from the
periimplantation porcine uterus by messenger ribonucleic
acid differential display: Temporal and conceptus-modu-
lated gene expression. Endocrinology 1996, 137:5447-5455.
44. Rodriguez-Sallaberry C, Simmen FA, Simmen RCM: Polyamine- and
insulin-like growth factor-I-mediated proliferation of porcine
uterine endometrial cells: A potential role for spermidine/
spermine N1-acetyltransferase during peri-implantation.
Biology of Reproduction 2001, 65:587-594.
45. Kim JE, Kim SJ, Lee BH, Park RW, Kim KS, Kim IS: Identification of
motifs for cell adhesion within the repeated domains of
transforming growth factor-beta-induced gene, betaig-h3. J
Biol Chem 2000, 275:30907-30915.
46. Rodgers WH, Matrisian LM, Giudice LC, Dsupin B, Cannon P, Svitek
C, Gorstein F, Osteen KG: Patterns of matrix metalloprotein-
ase expression in cycling endometrium imply differential
functions and regulation by steroid hormones.  J Clin Invest
1994, 94:946-953.
47. Osteen KG, Keller NR, Feltus FA, Melner MH: Paracrine regula-
tion of matrix metalloproteinase expression in the normal
human endometrium. Gynecol Obstet Invest 1999, 48:2-8.
48. Low KG, Nielsen CP, West NB, Douglass J, Brenner RM, Maslar IA,
Melner MH: Proenkephalin gene expression in the primate
uterus: regulation by estradiol in the endometrium.  Mol
Endocrinol 1989, 3:852-857.
49. Nusse R: Developmental biology. Making head or tail of
Dickkopf. Nature 2001, 411:255-256.
50. Miller C, Pavlova A, Sassoon DA: Differential expression pat-
terns of Wnt genes in the murine female reproductive tractPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Reproductive Biology and Endocrinology 2004, 2:54 http://www.rbej.com/content/2/1/54
Page 9 of 9
(page number not for citation purposes)
during development and the estrous cycle. Mech Dev 1998,
76:91-99.
51. Abu-Jawdeh G, Comella N, Tomita Y, Brown LF, Tognazzi K, Sokol
SY, Kocher O: Differential expression of frpHE: a novel human
stromal protein of the secreted frizzled gene family, during
the endometrial cycle and malignancy.  Lab Invest 1999,
79:439-447.
52. Tulac S, Nayak NR, Kao LC, Van Waes M, Huang J, Lobo S, Germeyer
A, Lessey BA, Taylor RN, Suchanek E, Giudice LC: Identification,
characterization, and regulation of the canonical Wnt sign-
aling pathway in human endometrium. J Clin Endocrinol Metab
2003, 88:3860-3866.
53. Krebs CJ, Jarvis ED, Chan J, Lydon JP, Ogawa S, Pfaff DW: A mem-
brane-associated progesterone-binding protein, 25-Dx, is
regulated by progesterone in brain regions involved in
female reproductive behaviors. PNAS 2000, 97:12816-12821.
54. Quackenbush J: Genomics. Microarrays--guilt by association.
Science 2003, 302:240-241.
55. Torres MST, Ace CI, Okulicz WC: Application of laser microdis-
section for analysis of gene expression in the rhesus
endometrium. Biology of Reproduction 2002, In Press:.